Barney Bishop, PhD is an associate professor in the Department of Chemistry and Biochemistry at George Mason University. Bishop received a PhD in chemistry from the University of North Carolina at Chapel Hill in 1997, where his graduate research focused on peptide chemistry. Bishop then joined the laboratory of Dr. Lynne Regan at Yale University as a postdoctoral associate where his research focused on protein engineering and biophysical characterization. From spring of 2001 until the fall of 2003, Bishop was a Senior Research Scientist at New River Pharmaceuticals, a specialty pharmaceutical company focused on the development of novel pro-drug and drug delivery technologies. New River Pharmaceuticals was acquired by Shire Pharmaceuticals in 2007.

Bishop joined the Department of Chemistry and Biochemistry at George Mason University in the fall of 2003. His current research interests include antimicrobial peptides, the design of novel therapeutic agents for combating infection, and development of new technologies and strategies for the discovery and identification of antimicrobials from biological and environmental samples.

Bishop currently serves on the scientific advisory boards of two companies: Kempharm, Inc., an early-phase biopharmaceutical company focused on the development of new and safer treatments for pain, AD/HD and other illnesses and Ceres Nanosciences, LLLP, a company focused on commercializing hydrogel technologies that have been developed by researchers at George Mason University.